Northwest Biotherapeutics (NWBO) Retained Earnings (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly Retained Earnings of -$429000.0 for Q1 2026, up 99.97% year-over-year from -$214531.5 in Q1 2025, and up 53.62% quarter-over-quarter from -$925000.0 in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Retained Earnings (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$429000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.97% year-over-year to -$429000.0; the TTM figure through Mar 2026 stood at -$429000.0 (up 99.97% YoY), while the FY2025 annual figure was -$925000.0, up 99.94% from the prior year.
- Retained Earnings for Q1 2026 stood at -$429000.0, up from -$925000.0 in the prior quarter.
- The five-year high for Retained Earnings was $6.3 million in Q3 2022, with the low at -$1.5 billion in Q1 2025.
- The 5-year median for Retained Earnings is -$925000.0 (2025), against an average of -$483.1 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings soared 543.61% in 2022, then plunged 68139.16% in 2025.
- Northwest Biotherapeutics' Retained Earnings stood at -$1.3 billion in 2022, then slipped by 4.83% to -$1.4 billion in 2023, then dropped by 6.16% to -$1.4 billion in 2024, then jumped by 99.94% to -$925000.0 in 2025, then soared by 53.62% to -$429000.0 in 2026.
- Business Quant data shows NWBO's Retained Earnings at -$429000.0 in Q1 2026, -$925000.0 in Q4 2025, and -$1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | -1.52 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.52 Bn |
| Mar 31, 2026 | -1.51 Bn |
| Dec 31, 2025 | -1.50 Bn |
| Sep 30, 2025 | -1.51 Bn |
| Jun 30, 2025 | -1.48 Bn |
| Mar 31, 2025 | -1.46 Bn |
| Dec 31, 2024 | -1.44 Bn |
| Sep 30, 2024 | -1.42 Bn |
| Jun 30, 2024 | -1.40 Bn |
| Mar 31, 2024 | -1.38 Bn |
| Dec 31, 2023 | -1.36 Bn |
| Sep 30, 2023 | -1.34 Bn |
| Jun 30, 2023 | -1.32 Bn |
| Mar 31, 2023 | -1.31 Bn |
| Dec 31, 2022 | -1.30 Bn |
| Sep 30, 2022 | -1.27 Bn |
| Jun 30, 2022 | -1.24 Bn |
| Mar 31, 2022 | -1.21 Bn |
| Dec 31, 2021 | -1.19 Bn |
| Sep 30, 2021 | -1.33 Bn |